+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338

Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338

European Journal of Pharmacology 497(2): 223-231

In the present study, the inhibitory properties of N-[2-(diisopropylamino)ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide monohydrochloride trihydrate (Z-338), a novel gastroprokinetic agent, were investigated and compared with those of cisapride to establish its potential for drug-drug interactions. There was no notable inhibition of terfenadine metabolism or of any of the isoforms of cytochrome P450 (CYP1A1/2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and 3A4) by Z-338 in in vitro studies using human liver microsomes. Z-338 was mainly metabolized to its glucuronide by UGT1A9 (UDP glucoronosyltransferase 1 family, polypeptide A9) and UGT1A8, and did not show marked inhibition of P-glycoprotein activity. On the other hand, cisapride strongly inhibited CYP3A4 and markedly inhibited CYP2C9. Furthermore, we used the whole-cell patch-clamp technique to investigate the effects of Z-338 and cisapride on potassium currents in human embryonic kidney (HEK) 293 cells transfected with the human ether-a-go-go-related gene (hERG). Z-338 had no significant effect on hERG-related current at the relatively high concentration of 10 microM. In contrast, the inhibition by Z-338 was very small compared with that of cisapride at 10 nM, which was a thousand-fold lower concentration. In the prediction method for the drug interaction between terfenadine and cisapride based on the K(i) and PK parameters, we suggest the possibility that terfenadine mainly affect the QT interval, since its plasma concentration would be markedly increased, but cisapride may not be changed. Thus, in contrast with cisapride, Z-338 did not inhibit CYP and the hERG channel, and is predominantly metabolized by glucuronide conjugation, Z-338 is considered unlikely to cause significant drug-drug interactions when coadministered with CYP substrates at clinically effective doses.

(PDF emailed within 0-6 h: $19.90)

Accession: 011978920

Download citation: RISBibTeXText

PMID: 15306208

DOI: 10.1016/j.ejphar.2004.06.040

Related references

The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metabolism and Disposition: the Biological Fate of Chemicals 28(10): 1231-1237, 2000

Cisapride a novel gastroprokinetic drug. Canadian Journal of Hospital Pharmacy 44(4): 175-181, 1991

In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development. Current Topics in Medicinal Chemistry 14(11): 1325-1338, 2015

A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Current Drug Metabolism 4(5): 411-422, 2003

Strategic proposals to avoid drug interactions during drug development: a lesson from a terfenadine-related drug interaction. Journal of Toxicological Sciences 21(5): 301-303, 1996

Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochemical Pharmacology 46(4): 559-566, 1993

Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin. Cell Biology and Toxicology 13(4-5): 365-374, 1997

Comparison of human liver slices to human liver microsomes as potential screening systems for terfenadine drug interactions. Clinical Pharmacology & Therapeutics 55(2): 138, 1994

Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicology In Vitro 10(6): 655-663, 1996

Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes. Methods in Molecular Biology 640: 281-294, 2010

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Current Drug Metabolism 9(5): 410-418, 2008

Characterization of in vitro metabolism of an anticancer agent E7389 Prediction of the potential risk of clinical drug-drug interactions. Drug Metabolism Reviews 35(Supplement 2): 184, 2003

Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharmaceutics & Drug Disposition 33(4): 179-194, 2012